Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia

INTRODUCTION: Gocovri (amantadine) extended release capsules are approved for treatment of dyskinesia and as a levodopa adjunct for OFF episodes in patients with Parkinson’s disease (PD). We report treatment-related effects on non-motor symptoms (NMS) assessed as secondary outcomes in two trials usi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Shyamal H., Pahwa, Rajesh, Tanner, Caroline M., Hauser, Robert A., Johnson, Reed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140024/
https://www.ncbi.nlm.nih.gov/pubmed/33864229
http://dx.doi.org/10.1007/s40120-021-00246-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140024/
https://www.ncbi.nlm.nih.gov/pubmed/33864229
http://dx.doi.org/10.1007/s40120-021-00246-3

Ejemplares similares